Related Experiment Video

Updated: Jun 6, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Highly Specific Modulators of Protein Kinase C Localization: Applications to Heart Failure

Nir Qvit1, Daria Mochly-Rosen

  • 1Department of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford CA 94305-5174.

Drug Discovery Today. Disease Mechanisms
|December 15, 2010
PubMed

Insights

Protein kinase C (PKC) plays a crucial role in heart failure (HF), a condition affecting 10% of adults over 65. Studying PKC regulators may reveal HF mechanisms and therapeutic targets.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biochemistry

Background:

  • Heart failure (HF) is a prevalent condition, particularly in individuals over 65, characterized by inadequate blood supply to meet the body's metabolic demands.
  • The protein kinase C (PKC) family comprises signaling enzymes vital for cellular functions, implicated in both normal physiological processes and various disease states.
  • Understanding the specific roles of PKC isoforms in cardiac pathophysiology is essential for developing targeted treatments.

Purpose of the Study:

  • To elucidate the role of protein kinase C (PKC) in the development of heart failure (HF).
  • To investigate the utility of specific PKC regulators in dissecting the underlying mechanisms of HF.
  • To identify potential therapeutic strategies for HF based on PKC modulation.

Main Methods:

  • Review and synthesis of existing literature on PKC signaling in cardiovascular disease.
  • Analysis of studies employing specific PKC modulators to probe HF mechanisms.
  • Exploration of preclinical and clinical data linking PKC activity to HF outcomes.

Main Results:

  • PKC signaling pathways are significantly altered in the failing heart, contributing to cardiac dysfunction.
  • Targeted modulation of specific PKC isoforms can impact cardiac contractility and remodeling.
  • Evidence suggests a complex, isoform-dependent role for PKC in HF pathogenesis.

Conclusions:

  • Protein kinase C (PKC) is a key player in the pathophysiology of heart failure (HF).
  • Specific PKC regulators offer valuable tools for mechanistic studies and represent promising therapeutic avenues for HF.
  • Further research into PKC isoform-specific functions is warranted for effective HF treatment development.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...